Clarify the Role of Paxlovid or Molnupiravir for COVID-19
February 2022
New oral antivirals will raise questions about treating COVID-19.
Use Paxlovid (nirmatrelvir/ritonavir) first-line for most outpatients with mild to moderate COVID-19, since it seems more effective...and molnupiravir when other options aren’t available.
Eligibility. Consider these meds for patients with a positive COVID-19 test who are at high risk of developing severe illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: MD includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote